BR9810555A - Derivados epotilona - Google Patents
Derivados epotilonaInfo
- Publication number
- BR9810555A BR9810555A BR9810555-8A BR9810555A BR9810555A BR 9810555 A BR9810555 A BR 9810555A BR 9810555 A BR9810555 A BR 9810555A BR 9810555 A BR9810555 A BR 9810555A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- group
- substituted
- aryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
"DERIVADOS EPOTILONA" A presente invenção refere-se a compostos de fórmula V caracterizado pelo fato de que: Q é selecionado do grupo que consiste de G é selecionado do grupo que consiste de alquila, alquila substituída, arila substituída ou insubstituída, heterociclo, W é O ou NR~ 15~; X é O ou H,H; Y é selecionado do grupo que consiste de O; H,OR~ 16~; OR~ 17~, OR~ 17~; NOR~ 18~; H,NOR~ 19~; H,NR~ 20~R~ 21~; H,H; ou CHR~ 22~; OR~ 17~OR~ 17~ pode ser um cetal cíclico; Z~ 1~, e Z~ 2~ são selecionados do grupo que consiste de CH~ 2~, O, NR~ 23~, S, ou SO~ 2~, onde apenas um de Z~ 1~ e Z~ 2~ pode ser um heteroátomo; B~ 1~ e B~ 2~ são selecionados do grupo que consiste de OR~ 24~, ou OCOR~ 25~, ou O~ 2~CNR~ 26~R~ 27~; quando B~ 1~ é H e Y é OH,H, os mesmos podem formar um anel cetal ou acetal de seis membros; D é selecionado do grupo que consiste de NR~ 28~R~ 29~, NR~ 30~COR~ 31~ ou heterociclo saturado; R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~, R~ 6~, R~ 7~, R~ 13~, R~ 14~, R~ 18~, R~ 19~, R~ 20~, R~ 21~, R~ 22~, R~ 26~, e R~ 27~ são selecionados do grupo que consiste de H, alquila, alquila substituída, ou arila e quando R~ 1~ e R~ 2~ são alquila podem ser unidas para formar uma cicloalquila; R~ 3~ e R~ 4~ são alquila podem ser unidas para formar uma cicloalquila; R~ 9~, R~ 10~, R~ 16~, R~ 17~, R~ 24~, R~ 25~ e R~ 31~, são selecionados do grupo que consiste de H, alquila ou alquila substituída; R~ 8~, R~ 11~, R~ 12~, R~ 28~, R~ 30~, R~ 32~, R~ 33~ e R~ 30~ são selecionados do grupo que consiste de H, alquila, alquila substituída, arila, arila substituída, cicloalquila, ou heterociclo; R~ 15~, R~ 23~ e R~ 29~ são selecionados do grupo que consiste de H, alquila, alquila substituída, arila, arila substituída, cicloalquila, heterociclo, R~ 32~C=O, R~ 33~SO~ 2~, hidróxi, O-alquila ou alquila O-substituída; os sais farmaceuticamente aceitáveis dos mesmos e quaisquer hidratos, solvatos ou geométricos, óticos e estereoisómeros dos mesmos, desde que os compostos onde W e X são ambos O; e R~ 1~, R~ 2~, R~ 7~ são H; e R~ 3~, R~ 4~, R~ 6~ são metila; e R~ 8~ é H ou metila; e Z~ 1~, e Z~ 2~, são CH~ 2~; e G é 1-metil-2-(4-tiazolil-substituída) etenila Q é como definido acima sejam excluídos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5195197P | 1997-07-08 | 1997-07-08 | |
| US6752497P | 1997-12-04 | 1997-12-04 | |
| PCT/US1998/012550 WO1999002514A2 (en) | 1997-07-08 | 1998-06-16 | Epothilone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR9810555A true BR9810555A (pt) | 2000-08-15 |
| BRPI9810555A8 BRPI9810555A8 (pt) | 2017-09-19 |
Family
ID=26729990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9810555A BRPI9810555A8 (pt) | 1997-07-08 | 1998-06-16 | Derivados epotilona |
Country Status (33)
| Country | Link |
|---|---|
| US (10) | US6605599B1 (pt) |
| EP (4) | EP1019389B1 (pt) |
| JP (2) | JP4090514B2 (pt) |
| KR (1) | KR100569041B1 (pt) |
| CN (1) | CN100384834C (pt) |
| AR (1) | AR013358A1 (pt) |
| AT (2) | ATE309236T1 (pt) |
| AU (1) | AU731497B2 (pt) |
| BG (1) | BG64952B1 (pt) |
| BR (1) | BRPI9810555A8 (pt) |
| CA (1) | CA2296012C (pt) |
| CO (1) | CO4940501A1 (pt) |
| CZ (1) | CZ297904B6 (pt) |
| DE (2) | DE69840693D1 (pt) |
| DK (1) | DK1019389T3 (pt) |
| EE (1) | EE04566B1 (pt) |
| EG (1) | EG24464A (pt) |
| ES (2) | ES2251088T3 (pt) |
| GE (1) | GEP20032897B (pt) |
| HK (2) | HK1026905A1 (pt) |
| HU (1) | HU227444B1 (pt) |
| ID (1) | ID23771A (pt) |
| IL (1) | IL133613A (pt) |
| LV (1) | LV12569B (pt) |
| MY (1) | MY124151A (pt) |
| NO (1) | NO322494B1 (pt) |
| NZ (1) | NZ501198A (pt) |
| PE (1) | PE104599A1 (pt) |
| PL (1) | PL197404B1 (pt) |
| RO (1) | RO120340B1 (pt) |
| TR (1) | TR200000065T2 (pt) |
| TW (1) | TW562802B (pt) |
| WO (1) | WO1999002514A2 (pt) |
Families Citing this family (161)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
| BR9713363B1 (pt) * | 1996-11-18 | 2011-02-08 | processo para preparação de epotilona d. | |
| WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| IL134419A0 (en) | 1997-08-09 | 2001-04-30 | Schering Ag | Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same |
| US6365749B1 (en) * | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| US6498257B1 (en) * | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
| US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
| WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| CA2352505C (en) | 1998-12-22 | 2009-04-07 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
| US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
| CZ20012886A3 (cs) * | 1999-02-11 | 2001-11-14 | Schering Aktiengesellschaft | Deriváty epothilonu, způsob jejich přípravy a jejich farmaceutické pouľití |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| BRPI0009721B8 (pt) | 1999-04-15 | 2021-11-23 | Bristol Myers Squibb Co | Inibidores de tirosina quinase de proteína cíclica |
| AU772750C (en) * | 1999-04-30 | 2005-02-24 | Schering Aktiengesellschaft | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| EP1229934B1 (en) | 1999-10-01 | 2014-03-05 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| DE10020899A1 (de) * | 2000-04-20 | 2001-10-25 | Schering Ag | 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| US6489314B1 (en) | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| AU2001266583A1 (en) * | 2000-05-26 | 2001-12-11 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| AU2002213248A1 (en) | 2000-10-13 | 2002-04-22 | The University Of Mississipi | Synthesis of epothilones and relates analogs |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| EE200300323A (et) | 2001-01-25 | 2003-10-15 | Bristol-Myers Squibb Company | Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine |
| CN100341505C (zh) | 2001-01-25 | 2007-10-10 | 布里斯托尔-迈尔斯斯奎布公司 | 用于治疗癌症的埃博霉素类似物的给药方法 |
| PL207720B1 (pl) * | 2001-01-25 | 2011-01-31 | Bristol Myers Squibb Co | Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej |
| US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| KR20040025895A (ko) | 2001-02-20 | 2004-03-26 | 브리스톨-마이어스스퀴브컴파니 | 에포틸론 유도체를 사용하는 치료불응성 종양의 치료 |
| HUP0400041A2 (hu) | 2001-02-20 | 2004-04-28 | Bristol-Myers Squibb Co. | Epotilonszármazékok alkalmazása makacs tumorok kezelésére szolgáló gyógyszerkészítmények előállítására |
| RU2003128953A (ru) | 2001-02-27 | 2005-03-10 | Гезелльшафт Фюр Биотехнологише Форшунг Мбх (Гбф) (De) | Деградация эпотилонов |
| WO2002072085A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| JP2004532888A (ja) | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| MXPA04006822A (es) | 2002-01-14 | 2004-12-08 | Novartis Ag | Combinaciones que comprenden epotilonas y anti-metabolitos. |
| EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
| AU2003218107A1 (en) * | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| DE60330651D1 (en) | 2002-03-12 | 2010-02-04 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
| TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| DE10232094A1 (de) * | 2002-07-15 | 2004-02-05 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | 5-Thiaepothilone und 15-disubstituierte Epothilone |
| DK1506203T3 (da) * | 2002-08-23 | 2007-05-14 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| BRPI0314133A8 (pt) | 2002-09-23 | 2017-09-19 | Bristol Myers Squibb Co | Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona |
| EP1553939A1 (en) * | 2002-10-11 | 2005-07-20 | Dana-Farber Cancer Institute, Inc. | Epothilone derivatives for the treatment of multiple myeloma |
| WO2004045518A2 (en) | 2002-11-15 | 2004-06-03 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
| DE60328516D1 (de) * | 2002-11-28 | 2009-09-03 | Wolfgang Richter | Thia-epothilon derivate zur krebsbehandlung |
| WO2004052361A1 (en) * | 2002-12-09 | 2004-06-24 | Novartis Ag | Microtubule stabilisers for treating stenosis in stents |
| GB0230024D0 (en) * | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
| CN101177425B (zh) * | 2003-01-28 | 2012-07-18 | 北京华昊中天生物技术有限公司 | 一类新型埃坡霉素化合物及其制备方法和用途 |
| DE602004028907D1 (de) | 2003-02-06 | 2010-10-14 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
| AU2008200555C1 (en) * | 2003-03-14 | 2011-12-15 | Novartis Ag | Treatment of proliferative diseases with epothilone derivatives and radiation |
| GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7371759B2 (en) | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| DE10344882A1 (de) | 2003-09-26 | 2005-04-21 | Morphochem Ag Komb Chemie | Neue Makrocyclen zur Behandlung von Krebserkrankungen |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| WO2005054429A2 (en) * | 2003-11-19 | 2005-06-16 | The University Of Mississippi | Synthesis of the c1-c6 keto-acid synthon of the epothilones |
| US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| EP1559447A1 (en) * | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
| US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| WO2006017761A2 (en) * | 2004-08-05 | 2006-02-16 | Emory University | Epothilone analogues as therapeutic agents |
| EP1640004A1 (en) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| KR20070084325A (ko) * | 2004-11-18 | 2007-08-24 | 브리스톨-마이어스 스큅 컴퍼니 | 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법 |
| US20060134214A1 (en) * | 2004-11-18 | 2006-06-22 | Ismat Ullah | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| CN101535492A (zh) | 2005-02-11 | 2009-09-16 | 南加州大学 | 表达含有二硫键的蛋白质的方法 |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2007117439A2 (en) | 2006-03-31 | 2007-10-18 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| WO2007130501A2 (en) * | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
| KR101506466B1 (ko) | 2006-05-16 | 2015-03-27 | 파마사이언스 인크. | Ｉａｐ ｂｉｒ 도메인 결합 화합물 |
| RU2009125599A (ru) | 2006-12-04 | 2011-01-20 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) | Композиции и способы лечения рака cpg-богатой днк и купредоксинами |
| CN101668536A (zh) | 2007-02-08 | 2010-03-10 | 伊利诺斯大学理事会 | 用铜氧还蛋白预防癌症的组合物和方法 |
| CN101754969A (zh) | 2007-05-25 | 2010-06-23 | 百时美施贵宝公司 | 制备埃坡霉素化合物和类似物的方法 |
| US20090076099A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched ixabepilone |
| EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
| DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
| EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
| ES2558568T3 (es) | 2008-01-08 | 2016-02-05 | Bristol-Myers Squibb Company | Combinación de anticuerpo anti-CTLA4 con agentes moduladores de la tubulina para el tratamiento de enfermedades proliferativas |
| PT2276485E (pt) * | 2008-04-24 | 2014-10-20 | Bristol Myers Squibb Co | Utilização de epotilona d no tratamento de doenças tauassociadas que compreendem a doença de alzheimer |
| US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
| EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
| JP4500951B1 (ja) * | 2009-08-07 | 2010-07-14 | 学校法人神戸学院 | Ｄｎａ合成酵素阻害剤 |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| AP2012006294A0 (en) | 2009-11-05 | 2012-06-30 | Rhizen Pharmaceuticals Sa | Novel kinase modulators. |
| RU2567544C2 (ru) | 2010-02-12 | 2015-11-10 | Фармасайенс Инк. | Bir домен iap связывающие соединения |
| ES2715611T3 (es) | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
| CA2927832C (en) | 2010-05-18 | 2021-03-23 | Cerulean Pharma Inc. | Cyclodextrin-containing polymer-therapeutic agent conjugates and their use |
| WO2011153221A1 (en) | 2010-06-01 | 2011-12-08 | Plus Chemicals Sa | Solid state forms of ixabepilone |
| CN101906099A (zh) * | 2010-07-16 | 2010-12-08 | 泰州市今朝伟业精细化工有限公司 | 一种埃博霉素d-内酰胺衍生物化学合成方法 |
| CA2824521C (en) | 2011-01-20 | 2016-06-28 | Board Of Regents, The University Of Texas System | Mri markers, delivery and extraction systems, and related methods |
| WO2012135278A2 (en) * | 2011-04-01 | 2012-10-04 | The Research Foundation Of State University Of New York | Olefin-triggered acid amplifiers |
| US20140193752A1 (en) * | 2011-04-01 | 2014-07-10 | The Research Foundation Of State University Of New York | Stabilized acid amplifiers |
| MX365160B (es) | 2011-05-04 | 2019-05-24 | Rhizen Pharmaceuticals Sa | Compuestos novedosos como moduladores de proteína cinasas. |
| JP2014516075A (ja) | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| TWI597065B (zh) | 2011-06-10 | 2017-09-01 | 梅爾莎納醫療公司 | 蛋白質－聚合物－藥物共軛體 |
| CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
| WO2013008091A1 (en) * | 2011-07-13 | 2013-01-17 | Xellia Pharmaceuticals Aps | Manufacturing of epothilone derivatives and the use thereof |
| ES2458220T3 (es) | 2011-09-12 | 2014-04-30 | Agfa-Gevaert | Métodos para el marcado por láser color de precursores de documento de seguridad |
| CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
| EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP2831073B1 (en) | 2012-03-30 | 2020-12-09 | Rhizen Pharmaceuticals S.A. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases |
| EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| EP2916872B1 (en) | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| CN104768962B (zh) | 2012-11-17 | 2017-04-05 | 北京市丰硕维康技术开发有限责任公司 | 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物 |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| AU2013359506B2 (en) | 2012-12-10 | 2018-05-24 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| TWI520956B (zh) * | 2013-03-08 | 2016-02-11 | 台灣神隆股份有限公司 | 伊莎匹隆及其中間體之製備方法 |
| AU2014228822A1 (en) | 2013-03-15 | 2015-10-01 | Memorial Sloan-Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
| EP3007692A1 (en) | 2013-06-11 | 2016-04-20 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CA2914189C (en) | 2013-06-21 | 2023-03-14 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CN115068626A (zh) | 2013-10-11 | 2022-09-20 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
| EP3054991B1 (en) | 2013-10-11 | 2019-04-03 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US10341459B2 (en) | 2015-09-18 | 2019-07-02 | International Business Machines Corporation | Personalized content and services based on profile information |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| CN111315414A (zh) | 2017-06-22 | 2020-06-19 | 梅尔莎纳医疗公司 | 产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法 |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
| WO2019212356A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B .V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| CA3099421A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
| US20230021500A1 (en) | 2018-10-29 | 2023-01-26 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| AU2020297253B2 (en) | 2019-06-17 | 2024-05-23 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
| WO2021142202A1 (en) | 2020-01-10 | 2021-07-15 | R-Pharm Us Operating Llc | Compositions of ixabepilone |
| WO2023031445A2 (en) | 2021-09-06 | 2023-03-09 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
| CA3238627A1 (en) | 2021-11-25 | 2023-06-01 | Christine Kohler | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
| EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
| WO2023104941A1 (en) | 2021-12-08 | 2023-06-15 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
| EP4372000A2 (en) | 2022-02-15 | 2024-05-22 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
| WO2024080872A1 (en) | 2022-10-12 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Strained bicyclononenes |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4272525A (en) | 1978-10-23 | 1981-06-09 | Schering Corporation | Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them |
| IL69666A (en) | 1982-09-13 | 1987-10-20 | Lilly Co Eli | 20-amino-20-deoxo-5-o-mycaminosyl-23-o-mycinosyltylonolide derivatives,their preparation and veterinary antibiotic use |
| US4820695A (en) | 1982-09-13 | 1989-04-11 | Eli Lilly And Company | C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| JPH03101679A (ja) | 1989-09-14 | 1991-04-26 | Sankyo Co Ltd | リゾキシン誘導体 |
| US5798345A (en) | 1990-09-21 | 1998-08-25 | Bone Care International, Inc. | Method of inhibiting the hyperproliferation of malignant cells |
| US5789397A (en) | 1991-01-08 | 1998-08-04 | Bone Care International, Inc. | Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2 |
| TW221028B (pt) | 1991-05-02 | 1994-02-11 | Lilly Co Eli | |
| US5217960A (en) | 1991-05-03 | 1993-06-08 | Abbott Laboratories | Erythromycin derivatives |
| JP3101679B2 (ja) | 1991-07-02 | 2000-10-23 | 株式会社ニチレイ | 動物細胞の凍結保存用血清不含培地及び保存方法 |
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| US5795882A (en) | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| TW226373B (pt) | 1992-07-15 | 1994-07-11 | Pfizer | |
| EP0586738A1 (en) | 1992-09-11 | 1994-03-16 | Boehringer Ingelheim Vetmedica Gmbh | Enhanced chemotherapeutic compositions against microbial infections in fish containing a benzylamine derivative and an antimicrobial substance |
| NZ250465A (en) | 1992-12-21 | 1995-10-26 | Lilly Co Eli | Bactericidal composition; contains macrolide antibiotic, use for treating aquatic species |
| WO1994021657A1 (en) | 1993-03-18 | 1994-09-29 | Pfizer Inc. | Antibacterial 16-membered ring macrolides containing olefins at c-20 |
| DE4316836A1 (de) | 1993-05-19 | 1994-11-24 | Knoell Hans Forschung Ev | Tetrahydrofuranyl-propionsäure, ein Verfahren zu ihrer Herstellung und Verwendung derselben |
| EP0708770B1 (en) | 1993-07-15 | 1997-04-16 | Pfizer Inc. | Amide derivatives of 16-membered ring antibiotic macrolides |
| SG49853A1 (en) | 1993-08-16 | 2001-07-24 | Novartis Ag | Novel macrolides and the use thereof |
| US5763429A (en) | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| AU3121095A (en) | 1994-09-22 | 1996-04-09 | Pfizer Inc. | Antibiotic macrolides |
| AU3953595A (en) | 1994-10-07 | 1996-05-02 | Merck & Co., Inc. | Process for assessing tubulin protein polymerization |
| IL117200A0 (en) | 1995-02-21 | 1996-06-18 | Schering Ag | Diethylenetriamine-pentaacetic acid monoamide derivatives pharmaceutical compostions containing the same and processes for the preparation thereof |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| US5515936A (en) * | 1995-07-10 | 1996-05-14 | Vehicules Ts Bellechasse Ltee | Track tensioning system for endless track propelled vehicle |
| DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
| DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
| ES2206607T3 (es) | 1995-11-17 | 2004-05-16 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Derivados de epotilones, preparacion y utilizacion. |
| WO1997019088A1 (en) | 1995-11-21 | 1997-05-29 | Hoechst Celanese Corporation | Novel nonlinear optical molecules and polymers incorporating them |
| EP0778283A3 (en) | 1995-12-05 | 1998-01-28 | Pfizer Inc. | Antibiotic macrolides |
| DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
| DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
| DE19636343C1 (de) | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
| AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
| GB9623944D0 (en) | 1996-11-15 | 1997-01-08 | Zeneca Ltd | Bicyclic amine derivatives |
| BR9713363B1 (pt) | 1996-11-18 | 2011-02-08 | processo para preparação de epotilona d. | |
| US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| AT404477B (de) | 1997-01-15 | 1998-11-25 | Thal Hermann Dipl Ing | Gebündeltes spannglied und verfahren zur herstellung desselben |
| DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
| CZ298027B6 (cs) | 1997-02-25 | 2007-05-30 | Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) | Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu |
| DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
| EP0975622B1 (de) | 1997-04-18 | 2002-10-09 | Studiengesellschaft Kohle mbH | Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium |
| DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
| DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| AU8542898A (en) | 1997-07-16 | 1999-02-10 | Schering Aktiengesellschaft | Thiazole derivatives, method for their production and use |
| IL134419A0 (en) | 1997-08-09 | 2001-04-30 | Schering Ag | Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| TW457095B (en) | 1998-02-05 | 2001-10-01 | Novartis Ag | Pharmaceutical formulations comprising epothilones and lyophilised compositions comprising epothilones |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| NZ506742A (en) | 1998-02-25 | 2003-09-26 | Sloan Kettering Inst Cancer | Synthesis of desoxyepothilones and hydroxy acid derivative intermediates |
| FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6136630A (en) * | 1998-06-04 | 2000-10-24 | The Regents Of The University Of Michigan | Method of making a micromechanical device from a single crystal semiconductor substrate and monolithic sensor formed thereby |
| WO2000000485A1 (de) | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
| WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| CA2352505C (en) * | 1998-12-22 | 2009-04-07 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
| ES2291194T3 (es) | 1999-02-18 | 2008-03-01 | Bayer Schering Pharma Aktiengesellschaft | Derivados de 16-halogeno-epotilones, procedimiento acerca de su preparacion y su utilizacion farmaceutica. |
| US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
| AR023792A1 (es) | 1999-04-30 | 2002-09-04 | Bayer Schering Pharma Ag | Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos |
| AU772750C (en) | 1999-04-30 | 2005-02-24 | Schering Aktiengesellschaft | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| CN100341505C (zh) | 2001-01-25 | 2007-10-10 | 布里斯托尔-迈尔斯斯奎布公司 | 用于治疗癌症的埃博霉素类似物的给药方法 |
| EE200300323A (et) | 2001-01-25 | 2003-10-15 | Bristol-Myers Squibb Company | Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine |
| KR20040025895A (ko) | 2001-02-20 | 2004-03-26 | 브리스톨-마이어스스퀴브컴파니 | 에포틸론 유도체를 사용하는 치료불응성 종양의 치료 |
| WO2002072085A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| US7026362B2 (en) | 2001-10-09 | 2006-04-11 | Simax Technologies, Inc. | Sol-gel process utilizing reduced mixing temperatures |
-
1998
- 1998-05-26 US US09/084,542 patent/US6605599B1/en not_active Ceased
- 1998-06-16 NZ NZ501198A patent/NZ501198A/en not_active IP Right Cessation
- 1998-06-16 GE GEAP19985171A patent/GEP20032897B/en unknown
- 1998-06-16 CA CA002296012A patent/CA2296012C/en not_active Expired - Lifetime
- 1998-06-16 EE EEP200000013A patent/EE04566B1/xx not_active IP Right Cessation
- 1998-06-16 WO PCT/US1998/012550 patent/WO1999002514A2/en active IP Right Grant
- 1998-06-16 EP EP98930300A patent/EP1019389B1/en not_active Expired - Lifetime
- 1998-06-16 AT AT98930300T patent/ATE309236T1/de active
- 1998-06-16 TR TR2000/00065T patent/TR200000065T2/xx unknown
- 1998-06-16 RO RO99-01332A patent/RO120340B1/ro unknown
- 1998-06-16 CZ CZ20000058A patent/CZ297904B6/cs not_active IP Right Cessation
- 1998-06-16 DK DK98930300T patent/DK1019389T3/da active
- 1998-06-16 IL IL13361398A patent/IL133613A/xx not_active IP Right Cessation
- 1998-06-16 ES ES98930300T patent/ES2251088T3/es not_active Expired - Lifetime
- 1998-06-16 JP JP50867399A patent/JP4090514B2/ja not_active Expired - Fee Related
- 1998-06-16 ID IDW20000002A patent/ID23771A/id unknown
- 1998-06-16 PL PL338003A patent/PL197404B1/pl unknown
- 1998-06-16 HU HU0103111A patent/HU227444B1/hu not_active IP Right Cessation
- 1998-06-16 DE DE69840693T patent/DE69840693D1/de not_active Expired - Lifetime
- 1998-06-16 ES ES04021059T patent/ES2322807T3/es not_active Expired - Lifetime
- 1998-06-16 BR BRPI9810555A patent/BRPI9810555A8/pt active Search and Examination
- 1998-06-16 EP EP04021059A patent/EP1493738B1/en not_active Expired - Lifetime
- 1998-06-16 EP EP04028580A patent/EP1526133A1/en not_active Withdrawn
- 1998-06-16 KR KR1020007000120A patent/KR100569041B1/ko active IP Right Grant
- 1998-06-16 AT AT04021059T patent/ATE426598T1/de not_active IP Right Cessation
- 1998-06-16 DE DE69832294T patent/DE69832294T2/de not_active Expired - Lifetime
- 1998-06-16 AU AU79720/98A patent/AU731497B2/en not_active Ceased
- 1998-06-16 CN CNB988069067A patent/CN100384834C/zh not_active Expired - Fee Related
- 1998-06-16 EP EP04028581A patent/EP1531153A1/en not_active Withdrawn
- 1998-07-02 TW TW087110722A patent/TW562802B/zh not_active IP Right Cessation
- 1998-07-07 EG EG79298A patent/EG24464A/xx active
- 1998-07-07 CO CO98038387A patent/CO4940501A1/es unknown
- 1998-07-07 PE PE1998000604A patent/PE104599A1/es not_active Application Discontinuation
- 1998-07-08 MY MYPI98003121A patent/MY124151A/en unknown
- 1998-07-08 AR ARP980103322A patent/AR013358A1/es active IP Right Grant
-
2000
- 2000-01-07 NO NO20000076A patent/NO322494B1/no not_active IP Right Cessation
- 2000-01-10 BG BG104068A patent/BG64952B1/bg unknown
- 2000-02-02 LV LVP-00-17A patent/LV12569B/en unknown
- 2000-09-26 HK HK00106086A patent/HK1026905A1/xx not_active IP Right Cessation
-
2001
- 2001-04-02 HK HK01102362.5A patent/HK1031731A1/xx not_active IP Right Cessation
-
2003
- 2003-04-03 US US10/405,886 patent/US7125899B2/en not_active Expired - Lifetime
-
2006
- 2006-08-30 US US11/512,623 patent/US7241755B2/en not_active Expired - Lifetime
-
2007
- 2007-06-13 JP JP2007156260A patent/JP4885067B2/ja not_active Expired - Fee Related
- 2007-06-15 US US11/763,636 patent/US8536327B2/en not_active Expired - Fee Related
-
2009
- 2009-08-11 US US12/539,496 patent/USRE41895E1/en not_active Expired - Lifetime
- 2009-08-11 US US12/539,492 patent/USRE41911E1/en not_active Expired - Lifetime
- 2009-08-11 US US12/539,498 patent/USRE41893E1/en not_active Expired - Lifetime
-
2010
- 2010-09-15 US US12/882,769 patent/USRE43003E1/en not_active Expired - Fee Related
-
2013
- 2013-08-14 US US13/966,613 patent/US8921542B2/en not_active Expired - Fee Related
-
2014
- 2014-11-25 US US14/553,081 patent/US20150080440A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9810555A (pt) | Derivados epotilona | |
| BRPI0407082A (pt) | Composto, pró-droga, produto farmacêutico, método de antagonizar hormÈnio liberador de gonadotropina, e, uso do composto | |
| SE8401134D0 (sv) | Forfarande for framstellning av dihydro-cyklosporin d | |
| BR9916781A (pt) | 4-oxo-1,4-dihidro-3-quinolinacarboxamidas comoagentes antivirais | |
| YU48390B (sh) | Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate | |
| KR890012970A (ko) | 테트라히드로 이소퀴놀린 유도체 | |
| EA200200098A1 (ru) | Ароматические сложные эфиры для маркировки или мечения нефтепродуктов | |
| RO93855A (ro) | Procedeu pentru prepararea de arilciclobutilalchilamina | |
| ES382552A1 (es) | Procedimiento para la preparacion de nuevas 2-aminoalcohi- lamino tieno (3,2-d) pirimidinas. | |
| WO1998006400A3 (en) | Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells | |
| WO2000051589A3 (en) | VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF | |
| EP0335979A4 (en) | Thienopyrimidine derivatives | |
| FI842081A (fi) | Tetrahydroisoxazolo/4,5- c/pyridinderivat samt farmaceutiska kompositioner. | |
| KR860004045A (ko) | 폴리사이클릭화합물의 제조방법 및 그 약학적 제제 | |
| ES500810A0 (es) | Procedimiento de preparacion de aminoalcoxipirazoles | |
| NO802925L (no) | Nitrosoureaderivater og fremgangsmaate ved fremstilling derav | |
| JPS55120575A (en) | Cis-2,3-epoxy-4-lower alkoxyphenylbutanoic acid derivative and its production | |
| ES2109936T3 (es) | Derivados de piperacina. | |
| ATE94050T1 (de) | Mittel zur verhinderung von zahnbelagbildung. | |
| JPS5412375A (en) | Derivative of pseudomonic acid | |
| MX9300585A (es) | Nuevos anmhidridos de acidos y procedimiento para su preparacion. | |
| AR008920A1 (es) | Proceso para la preparacion de los derivados de 2-amino-2-imidaxolina, guanidina, y 2-amino-3,4,5,6-tetrahidropiridimina | |
| DK0410224T3 (da) | Pyrrolo(2,1-b)thiazol-derivater | |
| DE69002352D1 (de) | Biphenylderivate. | |
| GB1316689A (en) | Trifamycin derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: ATRAVES DA PETICAO NO 024289 DE 22/05/2001, A REQUERENTE SOLICITOU O EXAME DO PRESENTE PEDIDO PARA06 (SEIS) REIVINDICACOES, E EFETUOU A RETRIBUICAO EQUIVALENTE A 10 (SEIS) REIVINDICACOES. ENTRETANTO, EM PETICAO NO 020070010812 DE 26/01/2007 FOI APRESENTADO UM NOVO QUADRO REIVINDICATORIO CONSTANDO DE 11 ( ONZE ) REIVINDICACOES. DESSE MODO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO O REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO EQUIVALENTE A 01 (UMA) REIVINDICACAO EXCEDENTE. O DEPOSITANTE DEVE RESPONDER A EXIGENCIA FORMULADA NESTE PARECER EM ATE 90 (NOVENTA) DIAS, A PARTIR DA DATA DE PUBLICACAO NA RPI, DE ACORDO COM O ART. 36 DA LPI. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
| B25A | Requested transfer of rights approved |
Owner name: R-PHARM US OPERATING, LLC (US) |